The link between abdominal obesity and the metabolic syndrome
Tóm tắt
Từ khóa
Tài liệu tham khảo
World Health Organization: Global strategy on diet, physical activity and health. Available at: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/ . Accessed November 2007.
Vague J: The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956, 4:20–34.
Wajchenberg BL: Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000, 21:697–738.
Alberti KG, Zimmet P, Shaw J: The metabolic syndrome—a new worldwide definition. Lancet 2005, 366:1059–1062.
Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752.
Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548–2556.
Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.
Xu H, Barnes GT, Yang Q, et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821–1830.
Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289–2304.
Galassi A, Reynolds K, He J: Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006, 119:812–819.
Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. In Report of a WHO Consultation. Geneva: World Health Organization, Department of Noncommunicable Disease Surveillance; 1999:1–59.
Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28:2745–2749.
Rosen ED, Spiegelman BM: Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006, 444:847–853.
Badman MK, Flier JS: The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 2007, 132:2103–2115.
Whitehead JP, Richards AA, Hickman IJ, et al.: Adiponectin—a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006, 8:264–280.
Richards AA, Stephens T, Charlton HK, et al.: Adiponectin multimerization is dependent on conserved lysines in the collagenous domain: evidence for regulation of multimerization by alterations in posttranslational modifications. Mol Endocrinol 2006, 20:1673–1687.
Yamauchi T, Kamon J, Ito Y, et al.: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762–769.
Yamauchi T, Kamon J, Minokoshi Y, et al.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288–1295.
Kubota N, Yano W, Kubota T, et al.: Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 2007, 6:55–68.
Hug C, Wang J, Ahmad NS, et al.: T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 2004, 101:10308–10313.
Takemura Y, Ouchi N, Shibata R, et al.: Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007, 117:375–386.
Yamauchi T, Nio Y, Maki T, et al.: Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332–339.
Xu A, Wang Y, Keshaw H, et al.: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91–100.
Covey SD, Wideman RD, McDonald C, et al.: The pancreatic beta cell is a key site for mediating the effects of leptin on glucose homeostasis. Cell Metab 2006, 4:291–302.
Chen K, Li F, Li J, et al.: Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 2006, 12:425–432.
Farooqi IS, O’Rahilly S: Is leptin an important physiological regulator of CRP? Nat Med 2007, 13:16–17; author reply 19–21.
Fukuhara A, Matsuda M, Nishizawa M, et al.: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426–430.
Varma V, Yao-Borengasser A, Rasouli N, et al.: Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007, 92:666–672.
Stephens JM, Vidal-Puig AJ: An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 2006, 17:128–131.
Ingelsson E, Larson MG, Fox CS, et al.: Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 2007, 30:1278–1280.
Korner A, Garten A, Bluher M, et al.: Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007, 92:4783–4791.
Yang RZ, Lee MJ, Hu H, et al.: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253–E1261.
de Souza Batista CM, Yang RZ, Lee MJ, et al.: Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655–1661.
Ma LJ, Mao SL, Taylor KL, et al.: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004, 53:336–346.
Hida K, Wada J, Eguchi J, et al.: Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005, 102:10610–10615.
Seeger J, Ziegelmeier M, Bachmann A, et al.: serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008, 93:247–251.
Bernstein LE, Berry J, Kim S, et al.: Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006, 166:902–908.
Arkan MC, Hevener AL, Greten FR, et al.: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11:191–198.
Weisberg SP, Hunter D, Huber R, et al.: CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006, 116:115–124.
Kanda H, Tateya S, Tamori Y, et al.: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006, 116:1494–1505.
Desbriere R, Vuaroqueaux V, Achard V, et al.: 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 2006, 14:794–798.
Shi H, Kokoeva MV, Inouye K, et al.: TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015–3025.
Nielsen S, Guo Z, Johnson CM, et al.: Splanchnic lipolysis in human obesity. J Clin Invest 2004, 113:1582–1588.
Fain JN, Madan AK, Hiler ML, et al.: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145:2273–2282.
Aronne LJ: Therapeutic options for modifying cardiometabolic risk factors. Am J Med 2007, 120:S26–S34.
Barzilai N, She L, Liu BQ, et al.: Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999, 48:94–98.
Klein S, Fontana L, Young VL, et al.: Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004, 350:2549–2557.